Title: Evaluation of Different Types of Face Masks to Limit the Spread of SARS-CoV-2 – A Modeling Study

Authors: Brian M. Gurbaxani, PhD*; Andrew N. Hill, PhD*; Prabasaj Paul, PhD; Pragati V. Prasad, MPH; Rachel B. Slayton, PhD.

*These authors contributed equally to this work

Affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Article Summary Line: Adapting a published SARS-CoV-2 transmission model together with updated, laboratory-derived source control and wearer protection efficacy estimates for a variety of face coverings as well as N95 respirators, we demonstrate that community masking as currently practiced has likely reduced cases and deaths and that this benefit can be increased with wider adoption of better performing masks.

Running Title: Evaluation of Face Masks to Limit SARS-CoV-2

Keywords: 2019 novel coronavirus disease; COVID-19; SARS-CoV-2; coronavirus; mathematical modeling; severe acute respiratory syndrome coronavirus 2; face masks.

All text: Times New Roman 12-pt. font; double-spaced and left aligned (left-justified).

Manuscript Number:

Abstract – WC 149 (Limit is 150!):

We updated a published mathematical model of SARS-CoV-2 transmission with laboratory-derived source and wearer protection efficacy estimates for a variety of face masks to estimate their impact on COVID-19 incidence and related mortality in the United States. When used at already-observed population rates of 80% for those ≥65 years and 60% for those <65 years, face masks are associated with 69% (cloth) to 78% (medical procedure mask) reductions in cumulative COVID-19 infections and 82% (cloth) to 87% (medical procedure mask) reductions in related deaths over a 6-month timeline in the model. If cloth or medical procedure masks' source control and wearer protection efficacies are boosted about 30% each to 84% and 60% by cloth over medical procedure masking, fitters, or braces, the COVID-19 basic reproductive number of 2.5 could decrease to an effective reproductive number ≤ 1.0, and from 4.0 to ≈ 1.6 for the B.1.1.7 variant.

Text – WC 3304

Introduction:

The emergence of coronavirus disease 2019 (COVID-19) has had a substantial impact on populations globally, with efforts across governments to prevent its remarkable spread. While social distancing has been universally recommended since very early in the pandemic, recommendations for masks in the general population were adopted later in many countries (see, for example, [1]). Several factors contributed to the initial uncertainty around the potential impact of widespread use of face masks on SARS-CoV-2 transmission. An 2015 large and well-designed study on cloth face masks (the main type of mask available to the public at the time) contributed to the scientific uncertainty that these types of face coverings were effective for

44 preventing the transmission of respiratory diseases [2]. There were initial hypotheses that cloth
45 masks could give the wearer a false sense of protection and even contaminate the wearer with
46 accumulated viral particles, notably described in a high-profile study in the *Annals of Internal*
47 *Medicine* that was later retracted (for failure to note PCR assay values that were below the limit
48 of detection) [3]. Furthermore, a major concern at the beginning of the outbreak in the US was
49 supply, especially of high-quality masks like N95 respirators. As it became clear, however, that
50 the virus can spread through exhaled respiratory droplets from infected individuals without
51 symptoms [4], the U.S. Centers for Disease Control and Prevention (CDC) recommended masks
52 for general use early in the U.S. pandemic (as of April 2020, [5]). Evidence continues to show
53 that asymptomatic and clinically mild infections contribute substantially to SARS-CoV-2
54 transmission [6-9]. Together, this growing body of evidence has highlighted the importance of
55 prevention measures, like masking, to reduce transmission from people who are asymptomatic,
56 undetected, or both.[6-8].
57 As the COVID-19 pandemic has continued, evidence has accumulated that face mask use by the
58 general population can limit the spread of SARS-CoV-2. This evidence has taken three main
59 forms, described in order of their appearance in the literature: 1) modeling studies that suggested
60 that even if masks are limited in their efficacy, widespread use across the population could still
61 reduce the spread of the virus to a considerable degree [10, 11], 2) laboratory studies that
62 demonstrated masks physically block exhaled droplets and aerosols containing virus from
63 infected persons (source control) and also offer wearer protection [12-14], and 3)
64 epidemiological studies that documented lower transmission in settings where masks were used
65 [15-19]. In this study, we extend the model of Worby and Chang to use age-stratified social
66 contact patterns for the general U.S. population, and we analyzed the model both employing the

measured face mask efficacy parameters for a variety of specific types of masks and for efficacy estimates that can act as benchmarks for evaluating these products [20].

Methods:

We adapted the transmission model (used for studying resource allocation of masks) of Worby and Chang (2020) for face mask adoption in a hypothetical population by expanding it to the age-stratified social contact patterns characteristic of the demographic profile of the United States. The underlying structure of this compartmental model is described in Worby and Chang [20], which we briefly summarize. Individuals are classified according to their disease status and whether or not they wear a mask in public. The model is further stratified by age in 5-year age bands. People contact each other (defined as either direct physical contact, e.g. through a handshake or a kiss, or a proximal, two-way conversation of 3 or more words) at age-specific daily rates estimated for the United States, as described by Mossong et al. and Prem et al. [21, 22]. Vaccination is not explicitly part of the model and has not been included in this study.

A schematic of the compartmental model is shown in Figure 1. Susceptible individuals who are infected move into an exposed compartment and thereafter into a pre-symptomatic compartment. Subsequently, a pre-specified proportion of these individuals moves into an asymptomatic state, while the remainder become fully symptomatic. Pre-symptomatic, asymptomatic, and fully symptomatic SARS-CoV-2 infected individuals all contribute to the force of infection with varying degrees of infectiousness. All asymptomatic individuals recover, whereas a proportion of fully symptomatic individuals do not recover and die. A fraction of asymptomatic cases is assumed to be detected whereupon a fraction of these individuals begins to use a mask and

90 continue to mask thereafter. Similarly, a fraction of symptomatic cases is assumed to know they
91 have COVID-19, and these individuals put on a mask at the same adoption level as detected in
92 asymptomatic cases. Symptomatic persons and detected, asymptomatic persons who wear a
93 mask also change their contact rates reflective of some degree of isolation/quarantine. We do not
94 include specific compartments modeling quarantine per se, but rather we reduce contact rates
95 which accomplishes the same purpose and maintains simplicity of compartmental structure while
96 allowing a degree of mixing that might be anticipated among a fraction of infected individuals
97 who are not strictly isolating themselves. We also assumed a fraction of the general population
98 adopts mask usage at the outset and continues usage regardless of infection status. Other than the
99 aforementioned masked cases, we assumed that contact rates among age groups remain the same
100 when people wear a mask. A basic reproduction number (R_0) of 2.5 was assumed in the absence
101 of any mask use, consistent with CDC's pandemic planning scenarios [23]. We also explored the
102 model with a basic reproduction number of 4.0, in keeping with the estimated magnitude of the
103 B.1.1.7 variant [24]. The modeled time horizon was 6 months and the cumulative number of
104 infections and deaths were recorded. The impact of various levels of mask adoption was assessed
105 by calculating the relative reduction in cumulative infection and deaths, comparing cumulative
106 cases and deaths to the same model over the same time horizon with no mask use in the entire
107 population.
108 Masks were modeled to reduce transmission via two different mechanisms: source control
109 efficacy, whereby mask wearing by an infectious person reduces their likelihood of transmitting
110 SARS-CoV-2; and wearer protection efficacy, whereby masks protect a susceptible person from
111 becoming infected when exposed to an infectious person. We examined adoption of various
112 kinds of masks (e.g., cloth, medical procedure, N95 respirators) specifically incorporating

estimates from a recent study of source control efficacy [14]. A range of values of hypothetical wearer protection efficacy was assumed for each kind of mask. Although it has generally been found that wearer protectiveness coefficients are approximately half the source control values [13, 25, 26], wearer protection efficacy was allowed to vary in the plot because it could be greatly affected by how the mask is worn, maintained, and used. Characteristics of each mask when worn according to manufacturers' specifications can be found in Lindsley et al. and are shown in Table 1 [14]. We do not address the issue of mask and respirator use in healthcare settings in this paper, as there is substantial public health guidance regarding the use of personal protective equipment in healthcare settings [27].

Results:

Figure 2 depicts heat maps of reduced transmission and deaths over 6 months as a function of varied source control efficacy and wearer protection efficacy. Mask wearing rates by the various sub-populations in the model are provided in the figure caption. These rates were in line with surveys of mask usage in the United States in May and June 2020 [28]. The colored bands of the plots represent contours of relative reduction. Going from the bottom left corner of the figures (source control efficacy and wearer protection efficacy both 0%, equivalent to no mask wearing in the population) these increase in 5% increments to the right top corner (source control efficacy and wearer protection efficacy both 100%). For example, to obtain at least a 50% reduction in cumulative infections, source control would need to be at least 55% efficacious in limiting transmission in the population for arbitrary wearer protection efficacy. Source control would need to be approximately 45% effective to reduce the number of deaths by half regardless of wearer protection efficacy.

136 Even with the source control and wearer protection efficacy for the types of mask that most
137 wearers are likely to use, such as medical procedure or cloth masks and gaiters (see Table 1),
138 substantial reductions in case load and death can be achieved with general population use at
139 stated levels. Even at lower levels of use, reductions are estimated to be substantial As source
140 control and wearer protection efficacy approach 100% for the masks, relative reduction in
141 infections also approaches 100%, even though mask adherence is far from 100%, because
142 transmission dips below the epidemic threshold (i.e. an effective reproduction number < 1). Our
143 simulations project that a 70% reduction in cumulative infections, relative to zero mask usage,
144 could be achieved with hypothetical combinations of wearer protection and source control
145 efficacies, respectively, of (0%, 65%), (25%, 50%), (40%, 35%), (50%, 25%), among many
146 others lying on the 70% contour curve of the left panel of Figure 2.
147 Figure 3 depicts the reduction in infections with different population-wide percentages of mask
148 use, with the assumption that mask wearer protection efficacy is half of source control efficacy
149 and that mask use among persons <65 years old is 70% that of persons ≥65 years old. Mask
150 wearing rates for detected and infected people are fixed at 90% for those ≥65 years old, and 70%
151 for those who are younger. Based on the model, if 25% of the general population ≥65 years old
152 puts on a mask, cumulative cases after 6 months are reduced by 23% (N95), 14% (medical
153 procedure), 12% (cloth), 12% (gaiter), and 9% (bandana). If mask adoption is 50% for the
154 general population ≥65 years old, projected reductions in cases are 57% (N95), 32% (medical
155 procedure), 28% (cloth), 28% (gaiter), and 20% (bandana). If mask adoption is 75% for ≥65
156 years old, projected reductions in cases are 95% (N95), 65% (medical procedure), 55% (cloth),
157 54% (gaiter), and 35% (bandana). Note that even with 0% mask use for the susceptible

158 population (horizontal axis), , there is still a small measure of infection control because of mask
159 adoption among detected infected people.
160 We estimated the incidence rate ratios (IRR) for new infections among mask wearers relative to
161 non-mask wearers over the course of 6 months, for different types of mask (Table 2). These
162 estimates reflect the impact of mask wearing on an individual wearer, whereas all of the other
163 analyses in this paper are focused on the population-level impact. The IRR at a given point in
164 time is the ratio of the number of new infections per capita among the mask wearing population
165 to the corresponding number among the non-mask wearing population. This assumes equal
166 mixing of masked and non-masked individuals – modeling the tendency for those populations to
167 self-segregate would tend to decrease these IRR values. As expected, the greater the mask
168 efficacy, the greater the difference in new infection rates as measured by the IRR. After 6
169 months, new infections are projected to occur at around half the rate among mask wearers
170 compared to those not wearing N95 respirators, whereas in a scenario where medical procedure
171 masks are worn, infections among mask wearers occur at around a 32% lower rate.
172 We evaluated the impact of face mask usage rates and efficacy parameters on the effective
173 reproduction number for $R_0 = 2.5$ and $R_0 = 4.0$, to represent the potential impact of novel
174 variants (e.g., B.1.1.7) (Figure 4) [24]. Note that warmer colors corresponding to higher
175 effective reproduction numbers are visible in the lower left-hand corner of the right panel but
176 less so in the left panel. As we approach 100% source control and wearer protection efficiencies,
177 masks reduce effective reproduction number < 1 for the low R_0 scenario, but not for the high R_0
178 scenario, given the same wearing percentages used to generate Figure 2. For example, when the
179 baseline $R_0 = 2.5$, an effective reproduction number of 1 is achieved by a hypothetical mask with
180 source control and wearer protection efficacies of 84% and 60%, respectively. However, these

181 same efficacies would result in an effective reproduction number of 1.6 when the baseline R_0 =
182 4.0. Those efficacies for masks are achievable with common cloth masks and medical procedure
183 masks if they are doubled up, if the cloth masks have filter inserts, or if either type of mask is
184 overfit with a fitter or brace to ensure a tighter fit [29-31]. If source control efficacy is 96% and
185 wearer protection efficacy is > 70% (in line with efficacies for N95 respirators) then the effective
186 reproduction numbers < 1.0 (R_0 = 2.5) and = 1.5 (R_0 = 4.0). Similarly, adoption of medical
187 procedure masks (source control efficacy 56%, wearer protection efficacy 28%), results in
188 effective reproduction numbers of 1.30 (R_0 = 2.5) and 2.07 (R_0 = 4.0).
189

190 **Discussion:**

191 Our results highlight the potential for substantial reduction in SARS-CoV-2 transmission, even
192 with moderately effective masks, when they are worn consistently correctly (over the chin and
193 covering nose and mouth) and/or per manufacturers' specifications by a large portion of the
194 population. These findings underscore the potential impact of population-wide measures that can
195 control transmission from infected individuals who do not have symptoms, both pre-
196 symptomatic individuals who are infectious prior to developing symptoms and individuals who
197 never experience symptoms. By extending the Worby and Chang model, we evaluated the
198 impact of different face mask use by age and highlight the need for wide adoption of these
199 interventions. Pairing this modeling framework with laboratory-derived parameters for source
200 control efficacy of different types of face masks helps to more accurately compare the relative
201 efficacy of each mask type as an intervention. Even with more specific source control
202 parameterization, the results are generally consistent with previous modeling studies [10, 11]:
203 face masks with realistic source control efficacy can reduce transmission substantially, and

204 widespread adoption can mitigate transmission at the population level. Furthermore, if the most
205 common types of face mask – cloth and medical procedure masks – can be enhanced with more
206 recent recommendations to improve fit around the nose and mouth, such as braces, elastic fitters,
207 or even double masking, those substantial reductions can be improved upon.
208
209 Our study and several others suggest that the magnitude of reduction in SARS-CoV-2
210 transmission increases non-linearly with increased mask usage. The reasons for the non-linear
211 multiplier effect are several, at least including potential epidemiological, immunological, and
212 behavioral mechanisms [17, 27, 31, 32]. Non-linear terms are inherent in the mathematical
213 mechanism of transmission reduction, given that masks act as both source control on the infected
214 and personal protection on the susceptible, terms which are multiplied together in the
215 transmission equations. This can be seen in the curvature of the line graphs of Figure 3 as mask
216 usage increases (diminishing returns can be seen as mask usage increases towards 100% for the
217 N95 respirators, however). Furthermore, it is hypothesized that there are non-linear effects
218 inherent in the pathogenesis of SARS-CoV-2 infection, in that masks reduce the initial viral
219 exposure even if a wearer becomes infected despite the mask, decreasing the severity of
220 infection, reducing viral load and shedding, and increasing the asymptomatic ratio [17, 32, 33]. If
221 this hypothesis is substantiated and we ignore complications arising from a higher asymptomatic
222 rate (i.e., more challenges with case identification), then there are potentially several non-linear
223 terms describing how the reproduction number decreases with mask efficacy and use. Lastly,
224 analysis of data on behavioral correlates of face mask use shows that people wear face masks
225 more often when they see others do so, even when they already intended to wear a mask [28]. If

226 changes in behavior were modeled, this would add another favorable non-linear term to the
227 impact of mask wearing.
228
229 The pandemic literature does contain a minority of reports that do not confirm the efficacy of
230 masks, although these studies have some important limitations. In particular, commentaries have
231 been written about the methodological limitations of a recent publication by Bundgaard et al. that
232 appears to question the efficacy of face masks [34]. [35, 36]. Specifically, the study was only
233 powered to test if the wearer protection efficacy of medical procedure masks (referred to as
234 "surgical masks" in Bundgaard et al.) was >50% and was not designed to measure their effect as
235 source control (because it was estimated only 5% of the population were wearing masks at the
236 time of the study). The Bundgaard et al. results were underpowered to detect wearer protection
237 efficacies of medical procedure and cloth masks. This is similar to another randomized
238 controlled trial (RCT) of cloth face masks as wearer protection against influenza virus infection
239 among healthcare workers by MacIntyre et al. [2]: the study was designed to evaluate only the
240 wearer protection effectiveness, not the source control effectiveness. Critically, the MacIntyre et
241 al. study did not compare cloth masks to no mask, only to masks of the health workers' choosing,
242 potentially including medical procedure masks. Hence, this RCT *in a healthcare setting* did not
243 have the negative control of not wearing a mask to help inform definitive conclusions about the
244 efficacy of cloth face masks for the general population in non-healthcare settings. In fact, a
245 follow-up study by MacIntyre et al. in 2020 found that healthcare workers whose cloth masks
246 were laundered by the hospital were protected as well as those who wore medical masks [37].
247 Also, recent results from an epidemiological study [38] analyzing population level mask

mandates where masks are more widely used are much more positive regarding the effectiveness of masks.

Limitations:

Despite widespread usage of masks and other mitigation strategies [39], transmission of SARS-CoV-2 remains inadequately controlled in the United States. There are many potential reasons why surveillance data and ecologic field studies might not show the magnitude of reduction in infections due to increasing mask usage predicted here. The parameters used in the models developed here might need to be better calibrated to match local transmission probabilities when individuals contact one another (either through direct physical contact, e.g. through a handshake or kiss, or a proximal, two-way conversation consisting of 3 or more words). Also, surveys indicating mask usage in the population may have overestimated adherence over time or the proper use or maintenance of masks. We model mask use as a set of parameters that can vary by age, but not by other societal subgroups, and our age groups were only divided into ≥65 years and <65 years. Furthermore, our model does not distinguish between differing contact rates within relevant populations such as schools, workplace, and households, but instead uses U.S.-national estimates for contact rates.

The source data for mask efficacy used in these models were derived from controlled laboratory simulations and not from human experiments. Measurements by other groups of filtration efficiency using actual human volunteers tend to show more variation, and in some cases the efficacies are lower than those reported here [40, 41].

Other limitations of the study are that mask usage is not assumed to vary over time, although it is likely that consistent and correct mask use may increase or decrease over time as individuals

change their behaviors. Thus, we model homogeneous and unchanging mask use in a limited number of subgroups vs. the reality that mask wearing is heterogeneous according to mask type, sub-population, maintenance and proper use, and many other time-varying characteristics. This may result in over-estimation of the impact of face masks on the pandemic. If so, even higher mask uptake would be necessary to achieve substantial reductions in cases than is indicated here. Although the post-holiday 2020-2021 surge in cases seems large given a fairly high rate of mask usage, we have no solid counterfactual information for comparison [12], i.e. we do not know what the results would have been with no mask usage.

Conclusions:

Modeling studies, including this analysis, have estimated how face masks can reduce transmission of SARS-CoV-2 and make a major impact at the population level, even with varying levels of adherence and effectiveness of masks. Multiple public health interventions are needed to reduce the transmission of SARS-CoV-2 and, as our analysis shows, robust use of face masks is an important contributor. Face masks of various materials have the potential to substantially reduce transmission in the SARS-CoV-2 pandemic, depending on the type of mask and the percentage adoption in the population. Public outreach and policies encouraging mask wearing, especially highly efficacious masks, need to be encouraged along with other prevention strategies (e.g., social distancing, hand washing, and vaccination). In fact, this study suggests that the current, imperfect use of masks has likely already reduced both cases and deaths.

Disclaimer: The findings and conclusions in this report are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

Author Bios:

Brian Gurbaxani is a computational biologist in the CDC's Office of Science, where he works with universities and academic partners to supply engineering, data modernization, and modeling solutions to the CDC community. A systems engineer, immunologist, and mathematical modeler by training, he co-chairs the CDC's Infectious Disease Modelers Community of Practice. Brian is also an adjunct professor of Industrial and Systems Engineering and Electrical and Computer Engineering at the Georgia Institute of Technology.

Andrew Hill leads the DM/Statistics Team in the Data Management, Statistics, and Evaluation Branch of the Division of Tuberculosis Elimination. He has worked on theoretical foundations of infectious disease models, with applications to TB, pertussis, and Ebola, as well as methods to estimate the prevalence of latent TB infection and performance of diagnostic tests. He has an adjunct appointment in the Biostatistics and Bioinformatics Department, Rollins School of Public Health, Emory University.

Supplement:

Methods

Transmission of SARS-CoV-2 is modeled by a system of ordinary differential equations (ODE) and compartments corresponding to age, disease status, and mask-wearing status. Compartments comprise susceptible (S), exposed (E), pre-symptomatic (P), asymptomatic and undetected (A_u), asymptomatic and detected (A_d), symptomatic (I), recovered (R), and deceased (D). The total

population is $N = S + E + P + A_u + A_d + I + R$. Initially, $N = 100{,}000$. Each of these compartments is further stratified by age (16 age groups from the POLYMOD study) and mask-wearing status (yes/no). Thus, each disease compartment is represented by a 16×2 matrix, with entries corresponding to the number of individuals of that particular disease status in age group $i = 1,\ldots,16$ and with mask status $j = 0$ (no mask), 1 (mask). In matrix form, the ODE system is:

$$
\begin{aligned}
\dot{\boldsymbol{S}} &= -q\left\{\boldsymbol{M}((\boldsymbol{I} + p_{\text{rel inf}}\boldsymbol{A}_d)\cdot[\mathbf{1}_{16}\ r\mathbf{1}_{16}] + p_{\text{rel inf}}(\boldsymbol{P}+\boldsymbol{A}_u))/N\begin{bmatrix}1 & 1-w\\ 1-s & (1-w)(1-s)\end{bmatrix}\right\}\cdot\boldsymbol{S}\\
\dot{\boldsymbol{E}} &= q\left\{\boldsymbol{M}((\boldsymbol{I} + p_{\text{rel inf}}\boldsymbol{A}_d)\cdot[\mathbf{1}_{16}\ r\mathbf{1}_{16}] + p_{\text{rel inf}}(\boldsymbol{P}+\boldsymbol{A}_u))/N\begin{bmatrix}1 & 1-w\\ 1-s & (1-w)(1-s)\end{bmatrix}\right\}\cdot\boldsymbol{S}\\
&\quad -\nu_E\boldsymbol{E}\\
\dot{\boldsymbol{P}} &= \nu_E\boldsymbol{E} - \nu_P\boldsymbol{P}\\
\dot{\boldsymbol{A}}_d &= p_{\text{asym}}\,p_{\text{detect}}\,\nu_P\left(\boldsymbol{P} + (p_{\text{inf mask use}}\cdot\boldsymbol{P})\begin{bmatrix}-1 & 1\\ 0 & 0\end{bmatrix}\right) - \nu_A\boldsymbol{A}_d\\
\dot{\boldsymbol{A}}_u &= p_{\text{asym}}\,(1-p_{\text{detect}})\,\nu_P\boldsymbol{P} - \nu_A\boldsymbol{A}_u\\
\dot{\boldsymbol{I}} &= (1-p_{\text{asym}})\,\nu_P\left(\boldsymbol{P} + (p_{\text{know}}p_{\text{inf mask use}}\cdot\boldsymbol{P})\begin{bmatrix}-1 & 1\\ 0 & 0\end{bmatrix}\right) - \nu_I\boldsymbol{I}\\
\dot{\boldsymbol{R}} &= \nu_A(\boldsymbol{A}_d + \boldsymbol{A}_u) + (1-p_{\text{death}})\,\nu_I\boldsymbol{I}
\end{aligned}
$$

Dot superscript denotes derivative with respect to time; central dot $\cdot$ indicates pointwise multiplication of matrices of the same dimension, or of the columns of a matrix by a vector of the same dimension.

Compartment durations are specified by a rate ν_J, where J is the compartment. Average duration in a compartment is $1/\nu_J$. These rates model the durations of days exposed (2 days), pre-symptomatic (4 days), asymptomatic (9 days), and symptomatic (9 days). Relative infectiousness of pre-symptomatic and asymptomatic persons compared to symptomatic persons is $p_{\text{rel inf}} = 0.75$. Detection probability of an asymptomatic case is $p_{\text{detect}} = 0.05$ and the proportion of

asymptomatic infections is $p_{asym} = 0.40$. The risk of death for symptomatic individuals was inferred from age-specific infection fatality ratios (IFR) via the equation CFR = IFR/$(1 - p_{asym})$, where CFR denotes the case fatality ratio. IFRs are 0.00003 for ages 0-19 years, 0.0002 ages 20-49, 0.005 ages 50-69, 0.054 ages 70 and older. These parameters are based on the September 2020 estimates included in the CDC Pandemic Planning Scenario #5 [23]. We further assume that 20% of symptomatic individuals know that that they are sick with SARS-CoV-2 and we denote this fraction by p_{know}. These people put on a mask.

POLYMOD daily contact rates were obtained from the study by Prem *et al.* [21]. The raw matrix of contact rates was adjusted in the usual fashion to maintain balance (numbers of contacts of age group i with age group j same as that of j with i). The raw matrix C is transformed to C' by

$$C'_{ij} = \frac{1}{2}(C_{ij} + C_{ji}N_j/N_i)$$

where N_i is the population size of age group i. Age distribution of the population was based on American Community Survey (ACS) estimates for the U.S. population [42]. Matrix C' is, in turn, transformed to give the symmetric matrix M in the ODEs by

$$M_{ij} = \frac{N}{2}(C_{ij}/N_j + C_{ji}/N_i) = C'_{ij}/(N_j/N)$$

In this formulation, a typical term in the force of infection (FoI) arising from an age-stratified infectious compartment $J = P, A_d, A_u, I$ of a given mask status is

$$(MJ)_i/N = \sum_{k=1}^{m} M_{ik} J_k/N = \sum_{k=1}^{m} C'_{ik} J_k/N_k$$

where $m = 16$ is the number of POLYMOD age groups corresponding to 5-year age bands ranging from younger than 5 years old to 70-75 years old, with the oldest age group comprising persons 75 years and older. The FoI is further stratified in the ODEs above depending on mask status. This is implemented by the 2×2 matrix appearing in the differential equations for S and E. This matrix governs reductions in the FoI according to source control efficacy (sce, or s for brevity) and wearer protection efficiency (wpe, or w) conferred by the mask type. These combine in four ways depending on the mask status of the infector and infectee (e.g., $1 - \text{wpe}$ and $1 - \text{sce}$ multiply together in the case of transmission by mask wearers to mask wearers). We further assume that symptomatic and detected, asymptomatic people who wear a mask have a lower, daily rate of contact. As contact rates in compartmental models apply to susceptible, not infectious, individuals, we model this as a reduction in infectiousness by a proportion r for both symptomatic and detected, asymptomatic mask-wearers. Specifically, if subscript i indexes age group and superscripts 'none' and 'mask' denote no mask and mask wearing, respectively, expanding the matrix formulation of the ODEs for susceptible individuals gives

$$\begin{aligned}
\dot{S}_i^{\text{none}} &= -q \sum_{k=1}^{m} M_{ik} (K_k^{\text{none}} + (1-\text{sce}) K_k^{\text{mask}}) \times S_i^{\text{none}}/N \\
\dot{S}_i^{\text{mask}} &= -q(1-\text{wpe}) \sum_{k=1}^{m} M_{ik} (K_k^{\text{none}} + (1-\text{sce}) K_k^{\text{mask}}) \times S_i^{\text{mask}}/N
\end{aligned}$$

where $K^{\text{none}} = I^{\text{none}} + p_{\text{rel inf}}(P^{\text{none}} + A_d^{\text{none}} + A_u^{\text{none}})$ and

$K^{\text{mask}} = r\, I^{\text{mask}} + p_{\text{rel inf}}(P^{\text{mask}} + r\, A_d^{\text{mask}} + A_u^{\text{mask}})$.

The age-specific vector $p_{\text{inf mask use}}$ (in the set of 7 ODEs specified at the beginning of this supplement) specifies the proportion of symptomatic and detected asymptomatic people who don a mask upon learning they are infectious. The corresponding proportion for symptomatic individuals is $p_{\text{know}} \times p_{\text{inf mask use}}$. The 2×2 matrix appearing in the differential equations for A_d and I governs the adoption of masks by asymptomatic individuals when they are detected (the first column corresponds to no mask, the second to mask wearing). In simulations, we assumed that individuals aged 65 years and older adopted masks at one proportion and younger than 65 years at another, lower, proportion (but this can be changed by the user). Expanding the matrix formulation of the ODEs for detected asymptomatic individuals gives

$$\begin{aligned} \dot{A}_{d,i}^{\text{none}} &= p_{\text{asym}}\, p_{\text{detect}}\, \nu_P (1 - p_{\text{inf mask use},i}) P_i^{\text{none}} - \nu_A\, A_{d,i}^{\text{none}} \\ \dot{A}_{d,i}^{\text{mask}} &= p_{\text{asym}}\, p_{\text{detect}}\, \nu_P (P_i^{\text{mask}} + p_{\text{inf mask use},i} P_i^{\text{none}}) - \nu_A\, A_{d,i}^{\text{mask}} \end{aligned}$$

It is assumed that a proportion of the general population (susceptible individuals) wear a mask at the outset and keep it on at all times (or at least when mixing in the population). This proportion can vary by age. We assume that in the general population, 80% of those aged 65 and older and 60% of the rest, wear a mask (and keep it on indefinitely).

To seed the epidemic, we arbitrarily assumed that there were 10 detected, asymptomatic non-masked individuals in each age group at the outset. Time units were expressed in days. The model was run for 6 months (183 days) with a timestep of 0.25 days using a Runge-Kutta solver in R v.3.6.3 [43] using the package 'deSolve' [44].

The FoI was calibrated to yield a basic reproduction number $R_0 = 2.5$ for the sub-model without mask usage. This yielded the parameter $q = 0.01429$, which represents the probability of a symptomatic infectious person infecting a susceptible person upon contact between them. The reproduction number was calculated as the dominant eigenvalue of the next-generation matrix (NGM) using the method of van den Driessche and Watmough [45]. Computation was facilitated by the R package 'blockmatrix' [46] owing to the sparseness of the matrices involved. Details of this calculation are described further below.

Calculation of R_0

Following [45], we construct matrices F, describing rates at which infectious individuals produce new infections, and V, consisting of all other rates, whose inverse describes average durations in compartments. The ith row and jth column of these matrices is the partial derivative of the right-hand side of the differential equation for compartment i with respect to compartment j, evaluated at the disease-free equilibrium (DFE). Only the 5 infected compartment types are considered, namely, E, P, A_d, A_u, I, enumerated by age group and mask status. The basic reproduction number R_0 is given by the dominant eigenvalue of the NGM $F\,V^{-1}$.

Matrices F and V are of dimension 160×160 (2 mask statuses $\times$ 16 age groups $\times$ 5 relevant compartment types). However, as new infections only arise from the E compartments, via the previously described FoI, matrix F is sparse. So too is V, as a lot of its sub-blocks are zero or diagonal matrices. Hence, we can construct these matrices in block form. We use the Kronecker product of matrices, which we denote by $\otimes$.

The DFE depends on the initial age-specific proportions, $p_{\text{susc mask use}}$, of the general, susceptible population wearing a mask. Multiplying the ACS age group proportions pointwise by $p_{\text{susc mask use}}$ and $1 - p_{\text{susc mask use}}$ gives the age-specific proportions of the population with and without masks,

respectively. These are multiplied by the hypothetical total population size $N = 100{,}000$ to obtain numbers in each stratum.

Vectorizing the 16 × 2 matrices in the ODEs by stacking columns into a single 32 × 1 column vector, we have the following constituent matrices for calculating R_0:

$$F_1 = \underbrace{\begin{bmatrix}1\\0\\0\\0\\0\end{bmatrix}}_{5\times1} \otimes \left\{ \left(\left\{ \underbrace{\begin{bmatrix}1\\1-w\end{bmatrix}}_{2\times1} \otimes \underbrace{[0\ p_{\text{ri}}\ p_{\text{ri}}\ p_{\text{ri}}\ 1]}_{1\times5} \otimes \underbrace{[1\ 1-s]}_{1\times2} \cdot \underbrace{G}_{2\times10} \right\} \otimes \underbrace{(M \cdot p_{\text{ACS}})}_{16\times16} \right) \cdot \underbrace{\begin{bmatrix}\mathbf{1}_{16} - p_{\text{smu}}\\ p_{\text{smu}}\end{bmatrix}}_{32\times1} \right\}$$

$$G = \begin{bmatrix}\mathbf{1}_5^{\mathsf{T}} & r & \mathbf{1}_3^{\mathsf{T}} & r\\ \mathbf{1}_5^{\mathsf{T}} & r & \mathbf{1}_3^{\mathsf{T}} & r\end{bmatrix}$$

For brevity, $p_{\text{r.i.}}$ denotes $p_{\text{rel inf}}$ above, p_{ACS} is the ACS population age distribution, $p_{\text{s.m.u.}}$ denotes $p_{\text{susc mask use}}$ above, w denotes WPE, s denotes SCE, $\mathbf{1}_n$ is the $n\times1$ vector of 1's, and · represents pointwise multiplication by column. Matrix M is the POLYMOD-derived contact matrix described earlier. It follows from the definition of Kronecker product that F_1 is 160 × 160. The order of entries in row or column vectors of length 5 corresponds to the compartment types E, P, A_d, A_u, I. Thus, the 5 × 1 vector on the left represents new infections only arising from compartments of type E (component 1) and not from P, A_d, A_u, I (components 2 to 5) and its occurrence renders F_1 sparse. The 1 × 5 row vector has components 2-4 as $p_{\text{rel inf}}$, indicating the relative infectiousness of presymptomatic and detected and undetected asymptomatic individuals (P, A_d, A_u) compared to symptomatic individuals I (component 5). Row and column vectors of length 2 correspond to mask efficacies. The vector p_{ACS} represents the population age-distribution and the 32 × 1 vector on the right denotes the age-specific general population mask wearing proportions.

The matrix F is given by $F = qF_1$, where q is the calibration parameter representing the probability of symptomatic infectious persons infecting susceptible persons upon contact between them.

Matrix V may also be expressed in block form as:

$$V = \begin{bmatrix} V_{EE} & 0 & 0 & 0 & 0 \\ V_{PE} & V_{PP} & 0 & 0 & 0 \\ 0 & V_{A_dP} & V_{A_dA_d} & 0 & 0 \\ 0 & V_{A_uP} & 0 & V_{A_uA_u} & 0 \\ 0 & V_{IP} & 0 & 0 & V_{II} \end{bmatrix}$$

where each block is a 32 × 32 matrix. Theory guarantees V is invertible. As with F, the order of the component types in block rows and columns here is E, P, A_d, A_u, I. The nonzero blocks are as follows, with parameter notation as given earlier, and I_n denoting the $n \times n$ identity matrix:

$$\begin{aligned}
V_{EE} &= \nu_E\, I_{32} \\
V_{PE} &= -\nu_E\, I_{32} \\
V_{PP} &= \nu_P\, I_{32} \\
V_{A_dP} &= -\nu_P\, p_{\text{detect}}\, p_{\text{asym}} B_A \\
\text{where } B_A &= \begin{bmatrix} \text{diag}(1 - \boldsymbol{p}_{\text{inf mask use}}) & 0 \\ \text{diag}(\boldsymbol{p}_{\text{inf mask use}}) & I_{16} \end{bmatrix} \ (16 \times 16 \text{ blocks}) \\
V_{A_dA_d} &= \nu_A\, I_{32} \\
V_{A_uP} &= -\nu_P\, (1 - p_{\text{detect}}) p_{\text{asym}} I_{32} \\
V_{A_uA_u} &= \nu_A\, I_{32} \\
V_{IP} &= -\nu_P\, (1 - p_{\text{asym}}) B_I \\
\text{where } B_I &= \begin{bmatrix} \text{diag}(1 - p_{\text{know}} \boldsymbol{p}_{\text{inf mask use}}) & 0 \\ p_{\text{know}} \text{diag}(\boldsymbol{p}_{\text{inf mask use}}) & I_{16} \end{bmatrix} \ (16 \times 16 \text{ blocks}) \\
V_{II} &= \nu_I\, I_{32}
\end{aligned}$$

Blocks V_{XX} on the leading diagonal correspond to outflows from compartment type X. Off-diagonal blocks V_{XY} correspond to inflows from compartment type Y to compartment type X. The B matrices correspond to the adoption of mask use (change of mask status) upon asymptomatic detection/symptomatic awareness, according to the age-specific proportion ($p_{\text{inf mask use}}$) who do so. Denoting the dominant eigenvalue of a matrix by ρ, we have

449 $R_0 = \rho(F\,V^{-1}) = q \times \rho(F_1 V^{-1})$.

450 Setting baseline $R_0 = 2.5$ (no mask use), we calibrate $q = 2.5 \div \rho(F_1 V^{-1})$.

451 ***Computation of symptomatic and asymptomatic detection rates***

452 The percentage of symptomatic and asymptomatic SARS-CoV-2 cases that are detected are not
453 established numbers, but they are suspected to be low given the general detection rate of 9.1%
454 [23] . Both can be estimated with a simple Bayesian calculation, however, given the general
455 detection rate (P(case) in the equation below), the asymptomatic rate of infections of 0.4 [23],
456 and the probability that detected cases are and remain asymptomatic (0.2) or symptomatic (0.8)
457 [47]. For example, the probability that you become a detected case (e.g. through contact tracing
458 efforts) given you are asymptomatic is given below

459 P(case|asymptomatic) = P(asymptomatic|case) P(case)/P(asymptomatic

460 The simple calculation yields a 5% detection rate for asymptomatic individuals and a 20%
461 detection rate for those with symptoms. The 20% figure appears to be in line with
462 epidemiological estimates as well [48].

463 **References:**

464

465 1. Brosseau, L.M., and Sietsema, M., *Commentary: Masks-For-All for Covid-19 Not Based on Sound*
466 *Data (University of Minnesota).* 2020.
467 2. MacIntyre, C.R., et al., *A cluster randomised trial of cloth masks compared with medical masks in*
468 *healthcare workers.* BMJ Open, 2015. **5**(4): p. e006577.
469 3. Bae, S., et al., *Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled*
470 *Comparison in 4 Patients.* Ann Intern Med, 2020. **173**(1): p. W22-w23.
471 4. Bai, Y., et al., *Presumed Asymptomatic Carrier Transmission of COVID-19.* JAMA, 2020. **323**(14):
472 p. 1406-1407.

5. Centers for Disease Control and Prevention. *Considerations for Wearing Masks*. 2020 December 18, 2020; Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html.
6. Byambasuren, O., et al., *Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis.* JAMMI, 2020.
7. Poletti, P., et al., *Probability of symptoms and critical disease after SARS-CoV-2 infection.* arXiv.
8. Oran, D.P. and E.J. Topol, *Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review.* Ann Intern Med, 2020. **173**(5): p. 362-367.
9. Johansson, M.A., et al., *SARS-CoV-2 Transmission From People Without COVID-19 Symptoms.* JAMA Network Open, 2021. **4**(1): p. e2035057-e2035057.
10. Ngonghala, C.N., et al., *Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus.* Math Biosci, 2020. **325**: p. 108364.
11. Eikenberry, S.E., et al., *To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic.* Infect Dis Model, 2020. **5**: p. 293-308.
12. Fisher, K.A., et al., *Factors Associated with Cloth Face Covering Use Among Adults During the COVID-19 Pandemic - United States, April and May 2020.* MMWR Morb Mortal Wkly Rep, 2020. **69**(28): p. 933-937.
13. Konda, A., et al., *Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks.* ACS Nano, 2020. **14**(5): p. 6339-6347.
14. Lindsley, W.G., et al., *Efficacy of face masks, neck gaiters and face shields for reducing the expulsion of simulated cough-generated aerosols.* Aerosol Science and Technology, 2020: p. 1-12.
15. Payne, D.C., et al., *SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore Roosevelt, April 2020.* MMWR Morb Mortal Wkly Rep, 2020. **69**(23): p. 714-721.
16. Hendrix, M.J., et al., *Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020.* MMWR Morb Mortal Wkly Rep, 2020. **69**(28): p. 930-932.
17. Ing, A.J., C. Cocks, and J.P. Green, *COVID-19: in the footsteps of Ernest Shackleton.* Thorax, 2020. **75**(8): p. 693-694.
18. Lyu, W. and G.L. Wehby, *Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US.* Health Aff (Millwood), 2020. **39**(8): p. 1419-1425.
19. Brooks, J.T. and J.C. Butler, *Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2.* Jama, 2021. **325**(10): p. 998-999.
20. Worby, C.J. and H.H. Chang, *Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic.* Nat Commun, 2020. **11**(1): p. 4049.
21. Prem, K., A.R. Cook, and M. Jit, *Projecting social contact matrices in 152 countries using contact surveys and demographic data.* PLoS Comput Biol, 2017. **13**(9): p. e1005697.
22. Mossong, J., et al., *Social contacts and mixing patterns relevant to the spread of infectious diseases.* PLoS medicine, 2008. **5**(3): p. e74-e74.
23. Centers for Disease Control and Prevention. *COVID-19 Pandemic Planning Scenarios*. 2020 September 10, 2020; Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html.
24. Volz, E., et al., *Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data.* 2021: p. 2020.12.30.20249034.
25. Chan, J.F., et al., *Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19).* Clin Infect Dis, 2020. **71**(16): p. 2139-2149.

26. Ueki, H., et al., *Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2.* mSphere, 2020. **5**(5).
27. Centers for Disease Control and Prevention. *Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic*. 2020 December 14, 2020; Available from: Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic.
28. Barile, J.P., et al., *Theory-based Behavioral Predictors of Self-reported Use of Face Coverings in Public Settings during the COVID-19 Pandemic in the United States.* Ann Behav Med, 2020.
29. Gandhi, M. and L.C. Marr, *Uniting Infectious Disease and Physical Science Principles on the Importance of Face Masks for COVID-19.* Med, 2021. **2**(1): p. 29-32.
30. Rothamer, D.A., et al., *Strategies to minimize SARS-CoV-2 transmission in classroom settings: Combined impacts of ventilation and mask effective filtration efficiency.* 2021: p. 2020.12.31.20249101.
31. Brooks, J.T., et al., *Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021.* MMWR Morb Mortal Wkly Rep, 2021. **70**(7): p. 254-257.
32. Gandhi, M. and G.W. Rutherford, *Facial Masking for Covid-19 - Potential for "Variolation" as We Await a Vaccine.* N Engl J Med, 2020. **383**(18): p. e101.
33. Sims, M.D., et al., *COVID-19 seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking.* Clin Infect Dis, 2020.
34. Bundgaard, H., et al., *Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial.* Ann Intern Med, 2020.
35. Laine, C., S.N. Goodman, and E. Guallar, *The Role of Masks in Mitigating the SARS-CoV-2 Pandemic: Another Piece of the Puzzle.* Ann Intern Med, 2020.
36. Frieden, T.R. and S. Cash-Goldwasser, *Of Masks and Methods.* Ann Intern Med, 2020.
37. MacIntyre, C.R., et al., *Contamination and washing of cloth masks and risk of infection among hospital health workers in Vietnam: a post hoc analysis of a randomised controlled trial.* BMJ Open, 2020. **10**(9): p. e042045.
38. Van Dyke, M.E., et al., *Trends in County-Level COVID-19 Incidence in Counties With and Without a Mask Mandate - Kansas, June 1-August 23, 2020.* MMWR Morb Mortal Wkly Rep, 2020. **69**(47): p. 1777-1781.
39. Hutchins, H.J., et al., *COVID-19 Mitigation Behaviors by Age Group - United States, April-June 2020.* MMWR Morb Mortal Wkly Rep, 2020. **69**(43): p. 1584-1590.
40. Clapp, P.W., et al., *Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic.* JAMA Intern Med, 2021. **181**(4): p. 463-469.
41. Mueller, A.V., et al., *Quantitative Method for Comparative Assessment of Particle Removal Efficiency of Fabric Masks as Alternatives to Standard Surgical Masks for PPE.* Matter, 2020. **3**(3): p. 950-962.
42. U.S. Census Bureau, *American Community Survey*, T. S0101, Editor. 2019, U.S. Census Bureau: data.census.gov.
43. R Core Development Team, *A language and environment for statistical computing.*, R.F.f.S. Computing., Editor. 2020.
44. Soetaert, K., T. Petzoldt, and R.W. Setzer, *Solving Differential Equations in R: Package deSolve.* 2010, 2010. **33**(9): p. 25 %J Journal of Statistical Software.

45. van den Driessche, P. and J. Watmough, *Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission.* Math Biosci, 2002. **180**: p. 29-48.
46. Cordano, E., *blockmatrix: Tools to solve algebraic systems with partitioned matrices. R package version 1.0.* 2014.
47. Buitrago-Garcia, D., et al., *Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.* PLOS Medicine, 2020. **17**(9): p. e1003346.
48. Smith, L.E., et al., *Adherence to the test, trace, and isolate system in the UK: results from 37 nationally representative surveys.* BMJ, 2021. **372**: p. n608.

Address for Correspondence:

Brian M. Gurbaxani, PhD. Address: 1600 Clifton Rd NE, Atlanta, GA 30333. Email: buw8@cdc.gov.

Andrew N. Hill, PhD. Address: 1600 Clifton Rd NE, Atlanta, GA 30333. Email: fyu7@cdc.gov.

Tables

Table 1: Parameter values used in the simulation

Parameter	Value [reference]
Percentage of uninfected persons wearing masks at the outset	Varies by scenario
Mask efficacy as source control:	[14]
N95 respirator	96%
Medical procedure mask	56%
Cloth mask	49%
Gaiter	48%
Bandana	33%

Percentage of asymptomatic detected cases and symptomatic cases who have been detected as COVID-19 cases who adopt mask use	<65 years old: 70% ≥65 years old: 90%
Percentage of symptomatic cases who know they have COVID-19	20% (see Supplement)
Average duration of incubation period	6 days [23]
Average duration of asymptomatic and symptomatic periods	9 days [23]
Relative infectiousness of asymptomatic cases/symptomatic cases	75% [23]
Percentage of infections that are asymptomatic	40% [23]
Probability of detecting asymptomatic case	5% (see Supplement)
Infection Fatality Ratio (IFR)	Ages 0–19: 0.00003 Ages 20–29: 0.0002 Ages 50–69: 0.005 Ages 70+: 0.054 [23]
Reduction in contact rate for symptomatic and detected asymptomatic persons wearing a mask	50%
Risk of death for symptomatic cases	See Supplement for calculation

583

584 **Table 2:** Incidence rate ratios (IRR) at 2-month intervals of new infections among masked vs.
585 non-masked population. Each row represents a scenario in which all mask-wearing individuals
586 are assumed to wear the specified type of mask. Wearer protection efficacy is assumed to be half
587 of source control efficacy. It assumes 60% of the susceptible population <65 years old are
588 wearing masks, 80% of those ≥65 years old wear masks, and both rates increase 10% for both
589 detected and infected persons (whether symptomatic or asymptomatic).

	2 months	4 months	6 months
Type of Mask	IRR		
N95 respirator	0.47	0.48	0.48
Medical procedure	0.66	0.67	0.69
Cloth Mask	0.69	0.70	0.72
Gaiter	0.69	0.71	0.74
Bandana	0.76	0.78	0.81

590 IRR=Incidence rate ratio

591 ## Figure Legends

592 **Figure 1:** Schematic of compartmental model. Compartments are susceptible (S, green),
593 exposed (E, yellow), infectious compartments (pre-symptomatic P, asymptomatic and detected
594 A_d, asymptomatic and undetected A_u, symptomatic I, pink), recovered (R, gray), and died (D,
595 gray). Superscript 'n' denotes no mask, and 'm' denotes mask.

596 **Figure 2:** Heat maps of the percentage reduction in cumulative infections at the end of 1 year
597 relative to no mask use in the population. Assumes 60% of the susceptible population <65 years
598 old are wearing masks, 80% of those ≥65 years old wear masks, and both rates increase 10% for
599 detectably infected persons (whether symptomatic or asymptomatic). The simulation posits that
600 20% of symptomatic infected people and 5% of asymptomatic infected individuals have been
601 detected by screening and are known to be carrying SARS-CoV-2. Mask efficacy parameters for
602 source control and wearer protection increase along the vertical and horizontal axes, respectively.
603 Reductions in cumulative infections over 6 months are shown on the left; reductions in deaths
604 are shown on the right.
605 **Figure 3:** The percentage reduction in cumulative infections after 6 months of simulation,
606 relative to no mask use in the population, as mask use varies in the general, susceptible
607 population for different types of face masks. Mask source control parameters are fixed
608 according to estimates for the given types, and wearer protection efficiency is assumed to be half
609 of source control effectiveness. In this analysis, younger susceptible persons are assumed to use
610 masks at 70% of the rate of persons ≥65 years old. Known infected people ≥65 years old are
611 masked at a 90% rate, with younger persons at 70%.
612 **Figure 4:** Effective reproduction number for given mask use by varying efficacy parameters
613 shown on the horizontal and vertical axes. This analysis assumes 90% and 70% mask use rates
614 for infectious and detected persons older and younger than 65 years of age, respectively, and
615 80% and 60% among susceptible persons for the same age breakdown. Asymptomatic detection
616 and symptomatic awareness fractions are given in Table 1. The baseline R_0 in the absence of
617 mask use is assumed to be 2.5 in the left panel and 4.0 in the right panel.
618



Figure 1


Reduction in infections (%) relative to no masks
%
Source control efficacy (%)
Wearer protection efficacy (%)
Reduction in deaths (%) relative to no masks
%
Source control efficacy (%)
Wearer protection efficacy (%)

Figure 2


Reduction in infections relative to no masks
Mask type (Source control efficacy)
N95 (96%)
Surgical (56%)
Cloth (49%)
Gaiter (48%)
Bandana (33%)
Population-level reduction in infections (%)
0
20
40
60
80
100
Mask adoption in general population 65+ (%)

Figure 3


Effective reproduction number
R_E
Source control efficacy (%)
Wearer protection efficacy (%)
Low R_0
High R_0
0
20
40
60
80
100
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0

Figure 4